The SVP of Clinical Development Fibrosis (Hepatology), reporting to the Chief Medical Officer, will oversee clinical research, medical management, and study execution for the Company’s clinical program for Lixudebart and is a key member of the Research and Development Leadership Team.
Alentis Therapeutics, the Claudin-1 Company, is on a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing a clinical pipeline of anti-Claudin-1 monoclonal antibodies. Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing much-needed medicines to patients suffering from solid tumors as well as kidney, liver, and lung fibrosis.
